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                                   INTRODUCTION
      Breast  conserving therapy is becoming widely used method for  treating breast 
cancer,  since  major  clinical  trials  have  demonstrated  that  subsequent  survival  was 
equivalent  to that of mastectomy. In breast  conserving therapy, post  operative breast 
radiation  has  been  reported  to  reduce  cancer  recurrence  in  the  breast.  Despite  the 
abundance of literature there has been no analysis of the outcomes of patient undergoing 
this procedure in patients from South India, we therefore present our experience with 
breast conservation surgery.
Breast cancer is the most common malignancy among females in our cancer registry.
 1983-
87CIR
1988-
92CIR
1993-
97CIR
1998-
02CIR
2003-
05CIR
Cervix 33.6 26.8 23.9 24.3 19.8
Breast 15.3 16.8 20.9 24.5 30.1
The number of patients undergoing breast conservation surgery is limited in our center 
because of               -
 1. Advanced stage of presentation
 2. Preference for mastectomy compared to conservation.
HOSPITAL CANCER REGISTRY-CANCER INSTITUTE (WIA)
TUMOR 
STAGE
1980-89 1990-2000 2004-05
NO % NO % NO %
I 30 1.4 58 1.3 17 1.4
II 447 21.3 884 21.9 345 29.1
III 908 43.2 1371 43.3 585 49.3
IV 454 21.6 412 15.5 101 08.5
SNP(stage 
not possible)
262 12.5 600 18.0 139 11.7
TOTAL 2101 100  3325 100 1187 100
AIM AND OBJECTIVES
1. To evaluate the outcome, pattern of failure and survival of breast conservation 
surgery performed at Cancer Institute.
2. To compare the recurrence, overall and disease free survival from neoadjuvant 
chemo and concurrent chemoradiation group.
     3.  To study the relationship of various risk factors influencing the outcome of    BCS 
REVIEW OF LITERATURE
    Although  radical  and  modified  radical  mastectomy  (MRM)  were  the  historical 
mainstay of the treatment for stage 1 and 2 breast cancer for decades and MRM continue 
to  be  appropriate  for  some  patients,  breast  conservation  treatment  has  become  the 
preferred method of treatment for many patients. The results of prospective randomized 
trial as well as the results of large retrospective non randomized studies from single 
institutions have demonstrated the equivalence of mastectomy and breast conservation 
treatment for appropriately selected patients in early breast cancer
PROSPECTIVE RANDOMISED TRIALS
    Six  modern  prospective  randomized  trials  have  compared  mastectomy  with 
conservative surgery and radiation for stage I and II breast cancer shown in table1,1-9
TABLE 1-Prospective randomised trials comparing conservative surgery and radiation 
with mastectomy for early breast cancer
Trial Treatment
period
Total no 
of patients
Stage Surgery 
for 
primary
Adjuvant 
therapy
Milan1,2 1973-80 701 I Q,RM CMF
Institute 
gustave-
roussy3
1972-1980 179 I WE,MRM NONE
NSABPB-
06 4,5
1976-84 1,219 I-II WE,MRM Mel
National 
cancer 
institute6
1979-87 237 I-II WE,MRM AC
EORTC 7,8 1980-86 868 I-II LE,MRM CMF
Danish 
breast 
cancer 
group 9
1983-89 904 I-III Q,WE, 
MRM
CMF,
Tam
Mel- Melphalan, Tam - Tamoxifen
Whole breast irradiation with doses of 45 to 50 Gy  was used in all trials, and boost to 
primary site was employed in five of  the six trials .in the national surgical  adjuvant 
breast and bowelproject(NSABP) trial ,a dose of 50 Gy was delivered to the entire breast 
without a boost, this trial required histological negative margin of resection for patients 
undergoing conservative surgery and radiation. For  the remaining five trials,the total 
dose to the  primary site was greater than or equal to 60 Gy. The resluts of these trials 
are presented in table 2 and 3
Table 2
Survival Comparisons for Conservative Surgery and Radiation (CS and 
RT) Versus Mastectomy in Prospective Randomized Trials
Trial
End 
point
In years
Overall Survival % Disease –free 
Survival % 
CS and 
RT
Mastectomy CS and 
RT 
Mastectomy
Milan 110 18 65 (NS) 65
Institut 
Gustave – 
Roussy3
15 73 (0.19) 65
NSABP B 
- 064 12 63 (012) 59
50 
(0.21) 49
 NCI  6 10 77(0.89) 75 72 (0.93) 69
EORTC 7 10 65 (NS) 66
D B 
Cancer 
Group 9
6 79 (NS) 82 70 (NS) 66
Table 3
Comparisons of Local Recurrence Following Conservative Surgery and Radiation (CS 
and RT) or Mastectomy in Prospective Randomized Trials
Trial Endpoint
CS and RT
%
Mastectomy
%
Milan 110
Cumulative incidence at 
18 years
7  (NS) 4
Institut Gustave – 
Roussy3
Cumulative incidence at 
15 years
9 (NS) 14
NSABP B - 064 Cumulative incidence 10 8
National Cancer 
Institute 6
Crude incidence median 
follow – up at 10.1 years
19 (0.01) 6 
EORTC 7 Actuarial at 10 years 20  (0.01) 12 
Danish Breast 
Cancer Group 9
Crude incidence median 
follow – up at 3.3 years
3 (NS) 4 
     There are no significant differences in overall and disease-free survival rates when 
comparing  the  two  treatments  in  any  of  the  trials.  In  particular,  patients  with 
histologicaly positive nodes treated with chemotherapy have not  been found to have 
improved survival rates when treated with mastectomy either in the NSABP B-6 trial or 
the MILAN  I trial. 5,10
      In four of the six randomized trials, there was no significant difference in the risk of 
a recurrence in the treated breast or chest wall following mastectomy. In the National 
Cancer Institute (NCI) trial, a significantly higher local recurrence rate was observed in 
the breast  conservation group.  However  in  this  trial,  only  gross  tumor excision  was 
required for study entry. Similarly EORTC trial, 81 percent of the patients in the BCS 
arm had T2 tumor and 48 percent had microscopically positive margins.
     Local  recurrence  after  breast  preservation  may  be  due  to  inappropriate  patient 
selection,  inadequate  surgery  or  radiation therapy or  biologically  aggressive  disease. 
Inadequate surgery may have contributed to the increased risk of breast recurrence in the 
NCI and the EORTC trials. Overall, the incidence of a recurrence in the treated breast 
ranges from 3 to 20 percent (table3). 3,4,6,7,9,10       The majority of failures in the treated 
breast  can  be  salvaged  with  mastectomy,  and  survival  following  such  treatment  is 
appropriately 70 percent at five years. Primary mastectomy does not guarantee freedom 
from local  recurrence  in  stage  I  and  II  breast  cancer.  The  incidence  of  chest  wall 
recurrence ranges from 4 to 14 percent.
      A desire to avoid local recurrence is not  a reason to encourage a patient  who 
otherwise is a good candidate for breast conservation to choose mastectomy, since the 
procedures are associate with an equal risk of local failure in appropriately selected and 
treated  women.  A meta-analysis  11 of  nine  prospective  randomized  trials  comparing 
conservative  surgery  and  radiation  to  mastectomy  has  demonstrated  no  survival 
differences. Local recurrence was reported in 6.2 percent of the mastectomy patients and 
in 5.9 percent of the patients treated with breast conservation.11 The randomized trials 
have also addressed the issue of second malignancy related to radiation. There has been 
no difference  in  the  incidence  of  contralateral  breast  cancer  or  a  second non breast 
cancer malignancy. 
      In addition to the randomized trials comparing breast conservation (with excision 
and  radiation)  with  mastectomy,  ten  randomized  trials  have  compared  conservative 
surgery alone with conservative surgery and radiation. The published results of nine of 
these trials are summarized in table 4 and 5.10,12-19
Table 4
Prospective Randomized Trials Comparing Conservative Surgery 
With and Without Radiation Therapy
Comparisons of local recurrence following conservative surgery and 
radiation  (CS  and  RT)  or  Mastectomy  in  prospective  randomized 
trials.
Trial
No of 
Pts
Tumor 
Size 
(cm)
Pathologic 
Nodal 
Status
Surger
y
Systemic 
Therapy
Swedish 12 381 < 2 N- Q None
Milan III10, 13 601 < 2.5 N – or N + Q CMF/Tam N+
Ontario 14 837 < 4 N - L None
NSABP B – 
064
1,265 < 4 N + or N - L 
L – Pam5FU 
for N+
NSABP B – 
2115
1,009 < 1 N- L Tam
Scottish 16 556 < 4 N – of N+ WE CMF /Tam N+
British 17 399 ≤  5 N – or N + WE CMF or Tam
BASO II 18 241 ≤  2 N- WE Tam
West 
Midlands 19
707 ≤  4 Clin N - WE Tamoxifen
Table 5
Local  Recurrence  and  Survival  in  Prospective  Randomized  Trials  Comparing 
Conservative Surgery With and Without radiation Therapy
                                    Breast 
                              Recurrence %
Overall Survival  % Interval Results 
Trial CS CS + 
RT
CS CS + RT Reported
Milan III 10,13 18 2 92 92 5 – year actuyrial
Swedish 12 24 9 78 78 10-year actuarial
Ontario 14 40 18 72 74 10-year actuarial
NSABP B-064 35 10 58 62 12-year actuarial
NSABP B-2115 12 6 Crude 6.1-year mean
Scottish 16
     Positive ER
    Negative ER
28 6 85 88 5-year actuarial
25 3
44 14
British 17 35 13 5-year actuarial
BASO II18 5 2 98 98 Crude 4-year median
West Midlands 19 13 4 Crude 2-year mean
    The trials vary with regard to patient selection, extent of surgery and radiotherapy, and 
the use of adjuvant systemic therapy. Quadrantectomy was employed in the Milan and 
Swedish studies, and adjuvant chemotherapy and /or tamoxifen was used in NSABP, 
MILAN,  BRITISH,  SCOTTISH,  AND  WEST  MIDLANDS  trials.  Despite  these 
differences all  of the trials demonstrated a reduction in the rate of recurrence in the 
breast in the irradiated group (an average crude rate of reduction of 84 percent, ranging 
73 to 97 percent). Recent metaanalysis of ten randomized trials comparing conservative 
surgery to conservative surgery and radiation reported an absolute reduction in breast 
recurrence  rates  with  radiation  of  17  percent  for  axillary  node negative  women(  25 
versus  7.8  percent)  and  19  percent  for  axillary  node  positive  women(35.4  vs16.1 
percent).11 The absolute benefit from radiation for any recurrence was 16 percent for 
node negative  group(44.7  vs  28.6  percent,  p= <.00001)  and  8  percent  for  the  node 
positive group (58 versus 49.8 percent, p=.002)
    Subset  analyses within these trials have identified older  women ( greater than 55 yrs 
of age ) with small primary infiltrating ductal tumors ( less than 1to 2 cm ) and negative  
axillary nodes that lack an extensive intraductal component (EIC) or lymphatic invasion 
as having  lowest risk of recurrence when radiation is omitted.10,12-14 In the  Swedish  trial 
,the breast recurrence rate at ten years in this subset of patients was 11 percent after 
quardrantectomy  alone,  compared  with  6  percent  for  quadrantectomy  and  radiation. 
Therefore,  even  in  the  lowest  risk  group,  radiation  decreased  the  risk  of  a  breast 
recurrence. In a single arm prospective study of 81 women (median age 66 years) with 
primary tumors less than or equal to 2 cm without an EIC or lymphatic invasion excised 
with negative margin greater than or equal to 1 cm and with negative axillary nodes 
treated without radiation, the crude recurrence rate was 23 percent (median follow up of 
7.2 years).20
     The NSABP B-21 addressed this question in axillary node negative women with 
primary tumor less than or equal to 1 cm. Patients were randomized to tamoxifen alone, 
radiation, or radiation and tamoxifen. With a median follow up of 6.1 years, ipsilateral 
breast  tumor  recurrence were reported in 12 percent of the 336 patients who received 
tamoxifen, 6 percent in the 336 women treated with radiation and  2 percent in the 337 
women  treated  with  tamoxifen  and  radiation.  15 there  was  no  difference  in  overall 
survival and cause specific survival. This study suggests that tamoxifen cannot replace 
radiation even in most favorable tumors.
     The British association of surgical oncology (BASO) II trial randomized women with 
primary tumors less than 2 cm, histologicaly grade1, and negative axillary nodes to wide 
excision  with  or  without  tamoxifen  or  wide  excision  and  radiation  with  or  without 
tamoxifen. With median follow up of 4 years, ipsilateral breast tumor recurrence rate in 
the 120 patients who did not received radiation was five percent compared with two 
percent  in  the  121  women  who  received  radiation.18  Radiation  therefore  appears  to 
benefit all women with early stage invasive breast cancers, although magnitude of this 
benefit varies depending upon the selection of the patients.
Non randomized studies
    The results of multiple, non randomized studies further support the equivalence of 
breast conservation treatment and mastectomy in appropriately selected patients (tables 
6 and 7)2,21-30
Table 6
Survival Following Conservative Surgery and Radiation for Early-stage 
Breast Cancer (Nonrandomized Studies)
Studies Number of Patients 10 – year Survival
Stage I and II
Fowble et al. 21 697 83
Haffty et al. 22 278 67
Leung et al. 23 493 68
Mansfield et al. 24 1,070 80†
Spitalier et al. 25 1,133 80
Stotter et al. 26 490 74
Kini et al. 27 390 74
Stage I
Dewar et al. *28 757 79
Veronesi et al. 2 1,232 78
Perez et al. 29 520 85†
Zafrani et al. *30 434 86
Kini et al. 27 281 88
Table 7
Recurrence in  the  Breast  After  Conservative Surgery and Radiation for 
Early – stage Breast Cancer (Nonrandomized Studies)
Study
Number of 
Patients
Maximum 
Primary Tumor 
Size (cm)
Breast 
Recurrence at 10 
years (%)
Gage et al31 1,628 5 13
Kurtz et al. 32,33 1,593 5 14
Meric34 1,236 5 10
Veronesi et al. 1 1,232, 2 8
Clark et al. 35 1,130 5 14
Mansfield et al 24 1,070 5 14
Dewar et al. 34 757 3 8
Fowble et al. 36 697 5 18
Fourquet et al. 37 518 5 11
Halverson et al. 38 511 5 14
Leung et al. 23 493 5 10
Haffty et al. 22 433 5 19
Kini et al. 27 390 5 10
      At ten years, overall survival has ranged from 67 to 88 percent depending upon the  
stage of the disease (table 6). Disease – free survival at ten years is approximately 70 
percent.  These series have also demonstrated excellent  long- term control within the 
treated breast with primary tumors less than or equal to 5 cm in diameter (table7). 1,2,22-
24,27,28,31-38 At  ten years , local recurrence rate ranges from 8 to 19 percent. For patients 
with negative margin of resection, the ten years actuarial risk of breast recurrence is 10 
percent or less. The overall survival and local control rates in the breast reported by 
these retrospective series are comparable to the results of the six prospective randomized 
trials.
     Neoadjuvant  chemotherapy offers  several  advantages  compared with traditional 
postoperative  regimens.  Invasive  breast  cancer  patients  have  significant  risk  of 
harboring occult micrometastatic disease in distant organs. Neoadjuvant chemotherapy 
allows for earlier exposure of these micrometastases to chemotherapy agents,  and an 
observed response to chemotherapy in the primary breast disease site indicates that the 
regimen  has  effective  antitumor  activity.  Additionally,  for  women  who  experience 
significant regression of their tumor, neoadjuvant chemotherapy can allow for a more 
conservative surgical procedure.
    NSABP B-18 trial  compared outcomes  between patients  receiving adjuvant  and 
neoadjuvant chemotherapy, using survival and breast conserving surgery as end points. 
In this study, more than 1500 women who had operable breast cancer were randomized 
to four cycles of doxorubicin and cyclophosphamide either pre- or post operatively, with 
9 years of follow up reported.  There were no significant difference in overall survival or 
disease  free  survival  between  women  who  received  neoadjuvant  chemotherapy  and 
women who received adjuvant chemotherapy, with overall survival for both groups was 
70% at 9 years of follow up. DFS for both groups ranged between 53%and 55%. Among 
women receiving neoadjuvant chemotherapy, tumor size was reduced in 80%, 36% had 
a complete clinical response, and 13% had a complete pathologic response. Survival 
rates were significantly higher among the complete pathologic responders compared to 
other subsets. Despite using a wide variety of chemotherapeutic agents, the majority of 
studies have shown that neoadjuvant chemotherapy offers similar overall survival and 
DFS compared with adjuvant regimens. Both DFS an OS from these studies range from 
55%to  89%.  A recent  meta-analysis  by  Mauri  et  al  summarized  nine  randomized 
controlled  trials  that  randomized  women  to  either  neoadjuvant  or  adjuvant 
chemotherapy. These authors report  no difference in mortality  between patients  who 
received neoadjuvant and adjuvant chemotherapy (RR-1.0, 95% CI, .9-1.12).
     One of the most important benefits of neoadjuvant chemotherapy is that it offers 
tumor  down-staging,  expanding  the  number  of  women  eligible  for  BCS,  but  the 
cosmetic results improved with smaller tumors. NSABP B-18 trial reported that women 
who received preoperative chemotherapy were significantly more likely to  receive a 
lumpectomy  compared  with  women  who  received  adjuvant  therapy  (60%  vs67%, 
p<.002),  with greatest  increase in lumpectomy rates among women who had tumors 
larger  than  5  cm.  Other  authors  have  studied  BCS  in  the  setting  of  neoadjuvant 
chemotherapy with comparable results. Rates of BCS range from 37%to 89%. In fact 
approximately one-quarter of women who are not initially eligible for BCS, but who 
receive neoadjuvant  chemotherapy,  may safely receive BCS following chemotherapy 
because of tumor shrinkage.
     There is not much evidence on concurrent chemoradiation in literature, however there 
are few studies, our own institute study published earlier by V. Shanta et al, shown that 
combination of radiation and chemotherapy achieved a tumor sterility rate of 45%  41. 
Other studies done in the University  of  Southern California  conducted a  pilot  study 
using continuous infusion of 5FU during radiotherapy in 35 patients with LABC. The 
overall  clinical  response  was  noticed  in  72 %.  The pathological  CR rate  was  20%. 
Johnny kao and colleagues reported the results from two consecutive phase I/II trials 
where concurrent  paclitaxel  +/-  vinorelbine with radiotherapy in unresectable  LABC 
shown  a  pathological  CR  was  46%.  Present  study  pathological  CR  following 
neoadjuvant concurrent chemoradiation was 56% 42. Formenti and colleagues reported a 
trial of forty four T3-T4 N0-3 breast cancers twice weekly with neoadjuvant radiation 
with concomitant twice weekly paclitaxel. A 16% complete pathological response rate43. 
There  is  no  literature  evidence  for  in-breast  recurrence  following  neoadjuvant 
chemoradiation in breast conservation surgery.
MATERIALS AND METHODS
Pooled data from patients undergoing breast conservation surgery for early breast cancer 
over a 11 year period from 1995 to 2005 was retrospectively evaluated and analyzed.
     A total number of breast cancer patients treated in our institute from 1995 to 2005 
was  5589,  of  this  1564  case  were  early  breast  cancer.  In  this  period  145  breast 
conservation surgery were performed from this early breast cancer group and selected 
stage  III  A patients.  The numbers  of  conservation  surgeries  are  low in  our  institute 
because of advanced stage at presentation and the preference for Mastectomy in our 
patients. 
     All patients underwent thorough clinical examination, with initial staging work-up, 
which included FNAC / Tru-Cut biopsy of primary lesion, for patients who underwent 
excision biopsy outside, the slides were reviewed in the institute. Routine hemogram, 
renal function test, liver function test, chest x-ray, electrocardiogram, CECT-chest, bone 
scan and echocardiogram were done for all patients. Predictive factors like estrogen and 
progesterone receptors and Cerb2 were done for some patients.
     Neoadjuvant treatment, like chemotherapy and concurrent chemoradiation were used 
in some patients. Chemotherapy regimens used were CMF, FAC, FEC and TAXANE 
based, alone or concurrently with radiation. Radiation dose used was 40 GY to Breast 
and Axilla as per our Institute protocol.
     Surgical treatment consisted of wide local excision and axillary dissection with gross 
tumor surgical margin of 2cm or more, frozen section was used to confirm negative 
margins. For patients who received neoadjuvant therapy underwent surgery after third or 
fourth  cycle  of  chemo  therapy,  patients  who  received  concurrent  chemoradiation 
underwent surgery after four weeks from last date of radiation. Patients, who underwent 
straight  surgery,  did  so  after  confirming  diagnosis  and  completing  staging  work-up. 
Those who underwent excision biopsy outside were reexcised with 2 cm gross margins.
    Surgical morbidity like seroma, marginal necrosis, wound infection and flap loss, 
hematoma  were  assessed  postoperatively.  Pathological  assessment  include  primary 
tumor size, histological type, grade, margin status, pathological response, lymph nodes 
dissected and involved.
ADJUVANT TREATMENT
    All patients received adjuvant treatment according to tumors characteristic, adjuvant 
treatment given are, radiation therapy –for those who received preoperative radiation 
,post operatively received boost to tumor bed doses of 20-30 GY, other patient received 
40 GY radiation to breast and axilla and boost to tumor bed  doses of 20-30GY. As 
indicated  radiation  to  SCL  and  INTERNAL  MAMMARY  NODES  are  used. 
Chemotherapy were used in indicated patients with various regimen like CMF, FAC, 
FEC, TAXANE based, totally 6 cycles were used ,  those patients who received  pre 
operatively completed  there remaining  cycle postoperatively. Hormone therapy like 
tamoxifen and aromatase inhibitors were used as indicated for 5 years duration.
FOLLOW UP
    All patients were followed up for 3monthly for first three years, and 6 monthly for 
next two years and yearly thereafter.  In each visit, history, through clinical examination 
was done,  annually ultrasound liver,  ipsilateral  and contra lateral  mammogram, liver 
function  tests  were  done.  Symptoms  oriented  investigations  were  done  whenever 
indicated.
STATISTICAL ANALYSIS
Done by actuarial methods calculated using SPPS software.
RESULTS
     Most of our study patients belongs to age group 30-50yrs . This  is one decade earlier 
than western population.
CLINICAL   CHARACTERSTICS OF PATIENTS
Variables No of pts %
Tumor size  1cm&<1cm
 1.1-2cm
 2.1-5cm
 >5cm
5
23
110
7
3.0
15.8
73.7
4.8
Stage Stage I
StageIIA
StageIIB
StageIIIA
17
51
66
11
11.7
35.7
45.5
7.5
Menopausal status Premenopausal
postmenopausal
92
53
63.3
36.5
Receptor status Positive
Negative
Unknown
60
68
17
41.3
46.8
11.7
Underwent excision 
biopsy outside
Yes
No 
51
94
35
65
TREATMENT CHARACTERSTICS
Out of 145 patients 23 patients underwent straight surgery and the rest received 
neoadjuvant therapy either as chemo alone or concurrent CTRT. 
No of 
pts
%
STRAIGHT SURGERY +POST OP RADIATION 23 15.9
 NEOADJUVANT CHEMOTHERAPY 41 28.3
NEOADJUVANT CHEMORADIATION 81 55.9
PATHOLOGICAL ASSESMENT FOLLOWING NEOADJUVANT TREATMENT 
(EXCLUDING PATIENTS WHO UNDERWENT EXICISION OUTSIDE)
PATHOLOGICAL 
RESPONSE
 NEO ADJUVANT 
CHEMOTHERAPY
%
NEOADJUVANT 
CHEMORADIATION 
%
            CR               6                 43
             PR             68                 52
     NO 
RESPONSE
            26                    5
COMPLICATIONS
• Radiation toxicity in CT-RT          -    grade III  desquamation  8(10%)
Among 81 patients in concurrent CT-RT   8 patients developed grade 3 desquamation, 
rest fell into grade 1&2 
Surgical morbidity 
SEROMA WOUND 
INFECTION
WOUND 
GAPING
STRAIGHT 4(17%) 3(13%) 3(13%)
NEOADJUVANT CHEMO 9(21%) 5(12%) 4(9%)
NEOADJUVANTCHEMORA
-DIATION
10(12%) 18(22%) 18(22%)
RECURRENCE
Recurrence pattern following breast conservation treatment.
14 patients developed  local recurrence.
Median time to recurrence is 31 months, duration range from   ( 7months- 89 months)
            
                  Site %
LOCAL  RECURRENCE 6.9
 NODAL RECURRENCE 2.8
DISTANT FAILURE 12.4
LOCAL RECURRENCE IN  CT &CTRT ARM
Local recurrence following neoadjuvant chemotherapy and concurrent chemoradiation
NEOADJUVANT CHEMOTHERAPY 9.5%
NEOADJUVANT  CONCURRENT 
CHEMORADIATION
7.5%
1
RECURRENCE IN RELATION TO INITIAL SIZE OF TUMOR
RECURRENCE 
PRESENT
NO 
RECURRENCE
TOTAL
<1cm O 5 5
1.1-2cm 2 (8.7%) 21(91.3%) 23
2.1-5cm 11(10%) 99(90%) 110
>5cm 1(14.3%) 6(85.7%) 7
14 131 145
                                Not statistically significant       p=.58
RECURRENCE IN RELATION TO MARGIN STATUS
RECURRENCE 
PRESENT
NO 
RECURRENCE
TOTAL
>1cm 11(9.2%) 108(90.8%) 119
1mm-10mm 1(4.8%) 20(95.2%) 21
Positive 
margin
2(40%) 3(60%) 5
p-value=.53
RECURRENCE IN RELATION TO STAGE GROUP
STAGE RECURRENCE 
PRESENT
NO 
RECURRENCE
TOTAL
I 2 (11.8%) 15(88.2%) 17
IIA 3 (5.6%) 48(94.4%) 51
IIB 8 (12.1%) 58(87.9%) 66
IIIA 1 (9%) 10(91%) 11
14 131 145
P-VALUE=.829
RECURRENCE IN RELATION TO MENSTRUAL STATUS
RECURRENCE 
PRESENT
NO 
RECURRENCE
TOTAL
PREMENOPAUSE 11(12%) 81(88%) 92
POSTMENOPAUSE 3(5.7%) 50(94.3%) 53
14 131 145
P-VALUE=.257
RECURRENCE IN RELATION TO RECEPTOR STATUS
RECURRENCE 
PRESENT
RECURRENCE 
ABSENT
TOTAL
ER ,PR- 
POSITIVE
4(6.7%) 56(93.3%) 60
ER,PR-
NEGATIVE 
9(13.2%) 59(86.8%) 68
UNKNOWN 
STATUS
1(5.9%) 16(94.1%) 17
14 131 145
P-VALUE=.254
RECURRENCE IN RELATION TO EXICISION OUTSIDE
RECURRENCE 
PRESENT
RECURRENCE 
ABSENT
TOTAL
EXICISION 
BX NOT 
DONE 
8 (8.5%) 86(91.5%) 94
DONE 6 (11.7%) 45(88.3%) 51
14 131 145
P-VALUE=.563
OVERALL SURVIVAL AND DISEASE FREE SURVIVAL
5 yrs and 10 yrs Overall survival and disease free survival in this study is 86.9%, 
82.9%and81.0%, 75.0% respectively,
     OVERALL 
SURVIVAL 
   DISEASES FREE 
SURVIVAL
  5 YRS 86.9%        81.0%
10YRS  82.9%      75.0%
5 yrs DFS-81% & OS-86%.
OVERALL SURVIVAL AND DFS IN SUBSET OF TREATMENT  GROUP
5 YRS  OVERAL 
SURVIVAL
5 YRS DFS
STRAIGHT SURGERY 83.4% 81%
NEOADJUVANT 
CHEMO
88.1% 86%
NEOADJUVANT 
CHEMORADIATION
88.6% 83%
                                                      P= .956                    P=.975

5  YRS OS AND DFS IN RELATION TO PATHOLOGICAL RESPONSE,  STAGE 
WISE, MENOPAUSAL AND RECEPTOR STATUS.
5 YRS 
DFS
P 
VALUE
5YRS 
OS
P-VALUE
PATHOLOGICALRESPONSE
             
                    CR
        
  PR& NO RESPONSE
         83.2%
  
         83.3%
P=.786
 86.4%
  85.0%
P=.698 
STAGE
              I
              IIA
              IIB
             IIIA
88.2%
84.7%
79.8%
88.8%
P=.841
93%
87.9%
86.9%
90.0%
P=.903
MENOPAUSAL
   PRE
  POST
83%
83.9%
P=.776 87%
89%
P=.7235
RECEPTORS
ER,PR POSITIVE
ER,PR-NEGATIVE
90%
83%
P=.6796 90%
83%
P=.455
DISCUSSION
       This study was conducted to analyses the results of breast conservation treatment 
performed in Cancer Institute (WIA) Chennai, South India. To evaluate the outcomes of 
breast conservation treatment compared to historical studies. Totally 145 patients were 
included,  out  of  which 16 %  of  patient  underwent  straight  surgery ,  28% received 
neoadjuvant chemotherapy and 56% received neoadjuvant chemoradiation  followed by 
surgery.
      Most of our study patients belong to 30-50 years of age group. This is one decade 
earlier than the western population. Breast conservation surgery was performed only for 
stage  I  to  IIIA.  Most  of  the  patients  were  in  stage  IIA and  IIB  (35.7%& 45.5%). 
Regarding receptor status 41% were receptor positive, 46.8% were receptor negative, 
with unknown receptor status around 11%
      Neoadjuvant chemotherapy and chemoradiotherapy often referred to as an emerging 
concept, has been practiced at the Cancer Institute since 1960. Multimodality treatment 
of LABC is the accepted standard care today. Primary chemotherapy has been reported 
widely in operable breast cancer and LABC.40
      Analysis  of  pathological  response  in  our  study  shows that  complete  response 
following neoadjuvant chemotherapy shown similar results with literature; it has been 
reported in literature that rates of complete pathological response ranges from 3-30 % 
with neoadjuvant  chemotherapy  alone,  with  promising results  seen with  dose-dense, 
multiagent chemotherapy. 
    There is not much evidence on concurrent chemoradiation in literature, however there 
are few studies, our own institute study published earlier by V.Shanta et al , shown that 
combination of radiation and chemotherapy achieved a tumor sterility rate of 45%  41. 
Other studies done in the university of southern California conducted a pilot study using 
continuous infusion of 5FU during radiotherapy in 35 patients with LABC. The overall 
clinical response was noticed in 72 %. The pathological CR rate was 20%. Johnny kao 
and  colleagues  reported  the  results  from  two  consecutive  phase  I/II  trials  where 
concurrent paclitaxel +/- vinorelbine with radiotherapy in unresectable LABC shown a 
pathological  CR  was  46%.  Present  study  pathological  CR  following  neoadjuvant 
concurrent chemoradiation was 56% 42. Formenti and colleagues reported a trial of forty 
four  T3-T4  N0-3  breast  cancer  twice  weekly  with  neoadjuvant  radiation  with 
concomitant twice weekly paclitaxel. A 16% complete pathological response rate.43 
   Complete pathological response excluding patients who underwent excision outside 
was in chemotherapy was 6% and chemoradiation group achieved 43%.  There is no 
literature  evidence  so  far  for  chemoradiation  for  early  breast  cancer.  This  increased 
complete pathological response does not translate into overall survival in our study.
      Commonest complications were seroma, wound infection and wound gaping. Wound 
infection  and  gaping  were  slightly  more  in  patients  underwent  concurrent 
chemoradiation as compared to straight or neoadjuvant chemotherapy which was not 
statistically significant. Jayananad SB et al studied wound morbidity after neoadjuvant 
chemotherapy  radiotherapy  in  breast  surgery  ,were  they  shown a  greater  than usual 
seroma collection for about 7- 10 days in about 15%  cases , no margin skin morbidity, 
such  as  skin  necrosis  or  breakdown of  incision  related  to  chemoradiation  ,  wound 
infection rate was 5.8% 44.
     The overall survival and disease free survival at 5 yrs was 86.1% and 81% and at 10 
yrs was 82.9% and 75 % respectively, survival rate of our study were similar to those 
found elsewhere  1,2,3,4,5,6,7,8,9  . Six modern prospective randomized trials have compared 
mastectomy with conservative surgery and radiation for stage I and II. NSABP B-06   at 
12 yrs follow up shows overall survival was 63% and disease free survival was 50%, In 
NCI and EORTC  at 10 yrs follow up OS was 77% and 65% .Danish breast cancer group 
at 6 yrs follow OS and DFS were 79% and 70%. Milan I at 18 yrs follow up OS was 
65%, DFS was not reported.
     Whole breast irradiation with doses of 45 to 50 Gy  was used in all trials, and boost to 
primary site was employed in five of  the six trials . In the national surgical  adjuvant 
breast and bowel project(NSABP) trial ,a dose of 50 Gy was delivered to the entire 
breast without a boost. For  the remaining five trials,the total dose to the  primary site 
was greater than or equal to 60 Gy.In our study,dose of 40 GY was deliverd to breast and 
axilla with boost dose 20-30 GY.
    The results of multiple, non randomized studies further support the equivalence of 
breast conservation treatment and mastectomy in appropriately selected patients. At ten 
years, overall survival has ranged from 67 to 88 percent depending upon the stage of the 
disease .Disease – free survival at ten years is approximately 70 percent.2,21-30
We  also  compare  the  overall  survival  and  disease  free  survival  in  patients  who 
underwent upfront surgery, neoadjuvant chemo and  neoadjuvant chemoradiation which 
did not reveal any statsitical difference.
     The local recurrence rate in our study was 6.9% and the distant failure rate was 
12.4%  which  is  comparable  with  historical  studies  1-9.comparing  our  study  with 
literature, in four of the six well conducted randomized trials, there was no significant 
difference  in  the  risk  of  a  recurrence  in  the  treated  breast  or  chest  wall  following 
mastectomy. In the National  Cancer Institute  (NCI) trial,  a  significantly higher local 
recurrence rate was observed in the breast conservation group. However in this trial, 
only  gross  tumor  excision  was  required  for  study  entry.  Similarly  EORTC trial,  81 
percent of the patients in the BCS arm had T2 tumor and 48 percent had microscopically 
positive margins.
     Local  recurrence after  breast  preservation may be due to inappropriate patient’s 
selection,  inadequate  surgery  or  radiation therapy or  biologically  aggressive  disease. 
Inadequate surgery may have contributed to the increased risk of breast recurrence in the 
NCI and the EORTC trials. Overall, the incidence of a recurrence in the treated breast 
ranges from 3 to 20 percent.     The majority of failures in the treated breast can be 
salvaged with mastectomy, and survival following such treatment is appropriately 70 
percent  at  five  years.  Primary  mastectomy  does  not  guarantee  freedom  from  local 
recurrence in stage I and II breast cancer. The incidence of chest wall recurrence ranges 
from 4 to 14 percent.
     A meta-analysis  11 of nine prospective randomized trials comparing conservative 
surgery and radiation to mastectomy has demonstrated no survival differences. Local 
recurrence was reported in 6.2percent of the mastectomy patients and in 5.9 percent of 
the patients treated with breast conservation.11 
    In addition to the randomized trials comparing breast conservation (with excision and 
radiation) with mastectomy, ten randomized trials have compared conservative surgery 
alone with conservative surgery and radiation.  The trials  vary with regard to patient 
selection, extent of surgery and radiotherapy, and the use of adjuvant systemic therapy. 
Quadrantectomy  was  employed  in  the  Milan  and  Swedish  studies,  and  adjuvant 
chemotherapy and /or tamoxifen was used in NSABP, MILAN, BRITISH, SCOTTISH, 
& WEST MIDLANDS trials. Despite these differences all of the trials demonstrated a 
reduction in the rate of recurrence in the breast in the irradiated group (an average crude 
rate of reduction of 84 percent, ranging 73 to 97 percent). Recent metaanalysis of ten 
randomized trials comparing conservative surgery to conservative surgery and radiation 
reported an absolute reduction in breast recurrence rates with radiation of 17 percent for 
axillary node negative women( 25 versus 7.8 percent) and 19 percent for axillary node 
positive  women(35.4  vs16.1  percent).11 The  absolute  benefit  from radiation  for  any 
recurrence was 16 percent for node negative group(44.7 vs 28.6 percent, p= <.00001) 
and 8 percent for the node positive group (58 versus 49.8 percent, p=.002).
   Subgroup  analysis  done  in  our  study  shown  that  breast  recurrence  following 
neoadjuvant chemoradiation is 7.5% and following  chemotherapy is 9.5%.There is no 
literature  evidence  for  in-breast  recurrence  following  neoadjuvant  chemoradiation  in 
breast conservation surgery.
Table
END 
POINT 
LOCAL 
RECURRENCE 
DFS % OS% 
OUR 
STUDY 
5YRS 6.9% 81% 86.9%
MILANI 18YRS 7% - 65%
INSTIUTE 
GU
15YRS 9% - 73%
NASBP06 12YRS 10% 50% 60%
NCI 10YRS 19% 72% 77%
EORTC 10YRS 20% - 65%
DBCG 6YRS 3% 70% 79%
Various factors studied in relation to recurrence in our study. None of the factors was 
statistically significant.
       The recurrence in relation to tumor size there were no recurrence in tumor size  
<1cm and most of the recurrence in the tumors with 2-5cm. In relation to margin, most 
of the recurrences occur in   margin more than 1 cm. Two out of 5 patients with positive 
margin developed recurrence.   
     Menopausal status, receptor status and prior excision outside does not influence in 
recurrence pattern. In literature various factors have been studied, like histology type, 
presence of necrosis, lymphovascular invasion, lymphocyte infiltration, the presence of 
DCIS  in  association  with  an  invasive  ductal  carcinoma,  margins  of  resection,  and 
pathologic nodal status.
     The presence of vascular or lymphatic invasion, tumor necrosis, and an inflammatory 
infiltrate has been associated in a few studies with a somewhat increased risk of breast 
recurrence.  This risk is approximately 10 to 15 percent at five years.   Some series have 
also found an increased risk of breast recurrence in patients with high histologic – grade 
tumors  compared with  low –  grade  tumors, although this  has  not  been  a  consistent 
finding. Histologic subtype other than invasive ductal carcinoma does not appear to be 
associated with an increased or decreased risk of breast recurrence.  
     The impact of the final resection margin on breast recurrence rates varies.  Long – 
term data on the use of breast – conserving therapy in patients with positive margins is 
limited.  In the majority of the reported series, positive margins of resection have been 
associated with an increased risk of breast recurrence, The variation in these results may 
be related to the extent of the surgical resection for the primary tumor, the presence or 
absence of an EIC, the definition of a positive margin, the number of margins that are 
positive, and the extent of the margin positivity.
     In the Milan II trial,  10 the breast recurrence rate for patients with positive margins 
was 12 percent for those undergoing a quadrantectomy compared with 17 percent for 
those whose primary surgical procedure was lumpectomy.  At the JCRT, patients with 
positive margins had a considerably higher risk of breast recurrence than patients with 
negative margins.  The eight – year crude rate of breast recurrence was 18 percent for 
patients with positive margins. Additional experience is needed to confirm this finding, 
and negative margins should be the goal of breast-conserving therapy
    Analyses of risk factor did not reveal any statistical significance with regards to 
outcome as measured by DFS and OS.
Our study results of breast conservation results comparable with literature, addition of 
neoadjuvant  therapy  especially  neoadjuvant  chemoradiation  did  not  show  any 
advantage. As for breast conservation surgery is concerned radiation therapy is a must . 
So, why not  radiation can be combined with chemotherapy in neoadjuvant protocol,  so 
that  we  can   reduce  the  duration  of  treatment?  Additional  experience  is  needed  to 
confirm this finding.  
CONCLUSION
  In conclusion in our study there was an increased pathological complete response and 
partial  response  in  patients  undergoing neoadjuvant  chemo radiation,  but  it  was  not 
translated into overall  survival  when comparing with neoadjuvant  chemotherapy and 
straight  surgery.  The  results  of  breast  conservation  surgery  from  our  institute  are 
comparable with those in literature. Since our study is limited by the small samples, it  
needs to be validated in a larger study.
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